These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38928347)

  • 21. Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.
    Benhaim L; Gerger A; Bohanes P; Paez D; Wakatsuki T; Yang D; Labonte MJ; Ning Y; El-Khoueiry R; Loupakis F; Zhang W; Laurent-Puig P; Lenz HJ
    Pharmacogenomics J; 2014 Apr; 14(2):135-41. PubMed ID: 23752739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer.
    Yousef AM; Zawiah M; Al-Yacoub S; Kadi T; Tantawi DA; Al-Ramadhani H
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):237-243. PubMed ID: 29845393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer.
    Tajima Y; Shimada Y; Kameyama H; Yagi R; Okamura T; Kobayashi T; Kosugi SI; Wakai T
    Jpn J Clin Oncol; 2017 Apr; 47(4):313-320. PubMed ID: 28100684
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Lapucci A; Perrone G; Di Paolo A; Napoli C; Landini I; Roviello G; Calosi L; Naccarato AG; Falcone A; Bani D; Mini E; Nobili S
    Oncol Res; 2021 Mar; 28(6):631-644. PubMed ID: 33208224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study.
    Su J; Dai B; Yuan W; Wang G; Zhang Z; Li Z; Liu J; Song J
    Cancer Chemother Pharmacol; 2020 May; 85(5):969-978. PubMed ID: 32314029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.
    Yeh CC; Lai CY; Chang SN; Hsieh LL; Tang R; Sung FC; Lin YK
    Int J Clin Oncol; 2017 Jun; 22(3):484-493. PubMed ID: 28044213
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy.
    Catalano C; da Silva Filho MI; Jiraskova K; Vymetalkova V; Levy M; Liska V; Vycital O; Naccarati A; Vodickova L; Hemminki K; Vodicka P; Weber ANR; Försti A
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):838-842. PubMed ID: 29762254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting the effect of 5-fluorouracil-based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles.
    Chen Q; Gao P; Song Y; Huang X; Xiao Q; Chen X; Lv X; Wang Z
    Cancer Med; 2020 May; 9(9):3043-3056. PubMed ID: 32150672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Hitre E; Budai B; Adleff V; Czeglédi F; Horváth Z; Gyergyay F; Lövey J; Kovács T; Orosz Z; Láng I; Kásler M; Kralovánszky J
    Pharmacogenet Genomics; 2005 Oct; 15(10):723-30. PubMed ID: 16141798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
    Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
    Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postoperative adjuvant chemotherapy is associated with a lower incidence of colorectal adenomas in patients with previous colorectal cancer.
    Lee HS; Kim SB; Lee HJ; Park SJ; Hong SP; Cheon JH; Kim WH; Kim TI
    Gastrointest Endosc; 2018 Mar; 87(3):688-694.e2. PubMed ID: 28431950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit.
    Thomas ML; Hewett PJ; Ruszkiewicz AR; Moore JW
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):343-51. PubMed ID: 26471980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
    Li S; Zhu L; Yao L; Xia L; Pan L
    BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer.
    Crozier JE; McKee RF; McArdle CS; Angerson WJ; Anderson JH; Horgan PG; McMillan DC
    Br J Cancer; 2006 Jun; 94(12):1833-6. PubMed ID: 16721360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
    Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T
    BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.
    Tsuji T; Hidaka S; Sawai T; Nakagoe T; Yano H; Haseba M; Komatsu H; Shindou H; Fukuoka H; Yoshinaga M; Shibasaki S; Nanashima A; Yamaguchi H; Yasutake T; Tagawa Y
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3700-4. PubMed ID: 14506161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor budding as a predictive marker for 5-fluorouracil response in adjuvant-treated stage III colorectal cancer.
    Akabane S; Shimizu W; Takakura Y; Kochi M; Taguchi K; Nakashima I; Sato K; Hattori M; Egi H; Sentani K; Yasui W; Ohdan H
    Int J Clin Oncol; 2021 Jul; 26(7):1285-1292. PubMed ID: 33881678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EMAST status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for Stage II/III colorectal cancer.
    Mohammadpour S; Goodarzi HR; Jafarinia M; Porhoseingholi MA; Nazemalhosseini-Mojarad E
    J Cell Physiol; 2020 Apr; 235(4):3604-3611. PubMed ID: 31549400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.